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ABSTRACT
Adoptive T cell based immunotherapy is gaining significant traction in cancer treatment. Despite its
limited success, so far, in treating solid cancers, it is increasingly successful, demonstrating to have a
broader therapeutic potential. In this paper we develop a mathematical model to study the efficacy of
engineered T cell receptor (TCR) T cell therapy targeting the E7 antigen in cervical cancer cell lines.
We consider a dynamical system that follows the population of cancer cells, TCR T cells, and IL-2.
We demonstrate that there exists a TCR T cell dosage window for a successful cancer elimination that
can be expressed in terms of the initial tumor size. We obtain the TCR T cell dose for two cervical
cancer cell lines: 4050 and CaSki. Finally, a combination therapy of TCR T cell and IL-2 treatment
is studied. We show that certain treatment protocols can improve therapy responses in the 4050 cell
line, but not in the CaSki cell line.
1. Introduction
Adoptive T cell therapy, also called cellular adoptive im-
munotherapy or T cell transfer therapy, is an immunother-
apy that uses T cells to help patients overcome diseases such
as cancer. In adoptive T cell therapy, T cells are typically
collected from the patient, engineered to improve their abil-
ity to target the patient’s cancer cells, and cultured to large
numbers before being introduced back to the patient [27, 12].
Adoptive T cell therapy includes tumor-infiltrating lympho-
cyte (TIL) therapy [7, 36], T cell receptor (TCR) T cell ther-
apy [9, 14, 45], and chimeric antigen receptor (CAR) T cell
therapy [15, 2]. The use of immune cells from donors is be-
ing studied as well. This therapy has been of growing inter-
est as a potential anti-cancer treatment in recent years. How-
ever, at present, its applicability has been mostly limited to
blood cancers. Recent studies are focusing on broadening
the applicability of the therapy to other types of cancer in-
cluding solid tumors [15, 27]. Other issues that are being
investigated are the enhancement of the T cell production
and activation, including the selection of T cell subsets, as
well as adjusting the clinical protocols.
Another challenge of T cell therapies include a phenom-
ena known as "exhaustion" [43, 19, 22]. Although Tumor-
infiltrating CD8+ T cells can attack tumors, high and sus-
tained antigen exposure often leads CD8+ T cells to a grad-
ual loss of their functionality. Exhausted tumor-infiltrating
lymphocytes (TILs) are characterized by progressive and hi-
erarchical loss of effector functions such as defects in pro-
duction of IL-2, IFN-훾 and chemokines, high proliferative
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capacity and ex vivo killing, sustained upregulation and co-
expression of multiple inhibitory receptors including the cy-
totoxic T lymphocyte-associated protein 4 (CTLA-4) and pro-
grammed cell death protein 1 (PD-1). They are also charac-
terized by altered expression and use of key transcription fac-
tors, metabolic dysregulation, and by their inability to transi-
tion to quiescence and acquire antigen-independent memory
T cell homeostatic responsiveness [43, 19, 44, 23]. Whereas
blocking CTLA-4 and PD-1 inhibitory receptor can reinvig-
orate exhausted T cell responses, resulting in improved pro-
liferation and function [1, 40]; deletion of nuclear factor TOX,
TOX2 and members of the NR4A family in tumor-specific T
cells in tumors can abrogate the exhaustion program [38, 39].
These studies demonstrated that T cell exhaustion was re-
versible rather than a terminal state. Thus, a better under-
standing of mechanisms of T cell development could poten-
tially be used to engineer T cells and control T cell exhaus-
tion.
Mathematicalmodels that describe the interaction of can-
cer and immune cells date back to [20], where a dynamical
system involving the tumor and cytotoxic T lymphocyteswas
studied. Periodic treatment and time delay were included
to model persistant oscillations in [41], followed by a sta-
bility analysis in [6]. Further developments of the model
included adding new types of cells, such as Natural Killer
(NK) cells and normal cells, as well as various cytokines
[17, 5, 24]. These models capture the immune escape of tu-
mors and explain multiple equilibrium phases of coexisting
immune cells and cancer cells. Although the parameteri-
zation and analysis become difficult, dynamical systems in
higher dimensions, stochastic models, agent-based and cel-
lular automata models, as well as partial differential equa-
tions have all been used to test different biological hypothe-
ses including multiple immune cell populations and signal-
ing molecules [29, 30, 16, 8]. The recent surge of clini-
cal trials and the success of adoptive immunotherapies in-
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spired the adaptation of these mathematical models to the
new therapies [18], including adoptive T cell therapies [42].
For instance, CD19 CAR T cell therapy targeting acute lym-
phoblastic leukemia ismodeled in [25] with a dynamical sys-
tem that also includes healthy B cell populations and circu-
lating lymphocytes. However, this model was not calibrated
with experimental data. CD19 CAR T cell therapy applied
to chronic lymphocytic leukemia is studied in [11] where the
relationships between CAR T cell doses and disease burden
are being explored. To study the cytokine release syndrome
(one of the primary side effects of CAR T cell therapy) a
dynamical system of nine cytokines responding to CAR T
cell therapy is developed and studied in [13]. More recently,
CAR T cell therapies for glioblastoma are modeled in [37].
Another approach to immunotherapy, immune checkpoint
inhibitor therapies are modeled in [28, 26, 33].
In this paper, we focus on engineered T cells therapy tar-
geting human papilloma virus (HPV) E7 antigen in solid tu-
mor that is developed and studied in [14]. The viral oncopro-
tein E7 is an attractive therapeutic target due to its construc-
tive expression in HPV-associated cancers but not in healthy
tissues. Through a uterine cervix biopsy of a woman with
cervical intraepithelial neoplasia II/III, Jin et al. discovered
anHPV-16 E7 antigen-specific, HLA-A*02:01-restricted TCR.
By reversing 훼 and 훽 chain and adding disulfide bond and
hydrophobic substitutions, this modified TCR demonstrated
high avidity for the target epitope and no perceptible cross-
reactivity against human peptides. In vitro, genetic engi-
neered T cells that express E7-targeting TCR demonstrated
effector T cell functions, including IFN-훾 production and
CD8 coreceptorâĂŞindependent tumor cell killing. In vivo,
immunodeficient, NOD/SCID 훾 (NSG) mouse model, E7
TCR-transduced T cells mediated regression of the CaSki
cell line (a HPV-16+ cervical cancer) at doses of 1 × 106
or 1 × 107 cells and repressed the 4050 cell line growth (a
HPV-16+ oropharyngeal cancer) at doses of 1 × 107 cells.
This antitumor activity could be enhanced by the addition of
systemic IL-2.
The goal of this study is to demonstrate the potential role
of mathematical modeling in improving the administration
of adoptive TCR T cell therapy for cancer treatment. In
Section 2, we present a cancer-immune interaction model
that follows the dynamics of cancer cells, TCR engineered
T cells, and the cytokine IL-2. We describe the model pa-
rameters and assumptions, and the procedure of sequential
model calibration. In Section 3.1, stability analysis of the
model is conducted, resulting with conditions for therapy
success. In Section 3.2, we study the dose-dependent re-
sponse of two cancer cell lines, 4050 and CaSki to TCR T
cell treatment. We demonstrate the existence of a TCR T
cell dose-dependent therapeutic window. The combination
of TCR T cell and IL-2 treatment is studied in Section 3.3,
where we investigate the effect of different IL-2 treatment
schedules, and show that IL-2 treatment given in a longer
period of time is effective in the 4050 cell line, but not in the
CaSki cell line. A summary and future outlook are provided
in Section 4.
2. Model
We denote cancer cells by 퐶(푡), TCR engineered T cells
by 푇 (푡), and the cytokine IL-2 by 퐼(푡). The dynamics of
cancer-immune interactions is then modeled as
퐶̇ = 푎퐶(1 − 푏퐶) − 푛푇퐶, (1)
푇̇ = 푠푇 (푡) − 푑푇 + 푝푇
퐶
푔 + 퐶
− 푚퐶푇 + 푝1푇
퐼
푔1 + 퐼
,
(2)
퐼̇ = 푠퐼 (푡) − 푘퐼 + 푝2퐼
푇
푔2 + 푇
. (3)
The system (1)–(3) is adapted from existing models de-
scribing the interaction of cancer cells and T cells [20, 17,
31].
In Eq. (1), the cancer is assumed to follow a logistic
growth with growth rate 푎 and tumor capacity 1∕푏. The in-
teraction between cancer cells and T cells results with a tu-
mor death that is induced by the T cells with death rate 푛.
The TCR T cell therapy is represented by a source term
푠푇 (푡) in Eq. (2). These cells die exponentially at rate 푑. Theengineered TCR T cells are activated by the presence of the
cancer cells with E7 antigen, that is modeled with the param-
eter 푝 denoting the rate of proliferation of T cells induced by
cancer. The saturation of this proliferation for large values
of cancer cells follows a Michaelis-Menten dynamics, and is
given by 푔, a parameter that represents the number of cancer
cells that reduce the maximal T cell activation by half. In
addition, we assume that the interaction between cancer and
T cells further reduces the T cell population at a rate 푚.
In Eq. (3), the IL-2 therapy ismodeled similarly to Eq. (2)
with a source term 푠퐼 (푡) and a decay rate 푘. The model in-cludes the interaction between IL-2 and T cells, where we
assume that the two populations stimulate each other. Al-
though the effect of IL-2 on T cells is known to be both
stimulating and inhibitory [4], we assume that the net effect
is positive. This is supported by the data of [14]. The rates of
T cell and IL-2 production stimulated by each other are de-
noted as 푝1 and 푝2, respectively. We also assume saturationin the growth dynamics of T cells and IL-2 with parameters
푔1 and 푔2.The treatments are given as follows. The T cell treat-
ment is given once at the initial time 푡0 = 0, while the IL-2treatment is given 푑 times at times 푡1, ..., 푡푑 . Accordingly,the source terms are defined as
푠푇 (푡) = 푠̄1ퟏ푡=푡0 (푡), 푠퐼 (푡) =
푑∑
푖=1
푠̄2ퟏ푡=푡푖 (푡).
The model parameters and their biological interpreta-
tions are summarized in Table 1.
2.1. Sequential model calibration
The experimental data in [14] was obtained in three ex-
perimental settings: (1) cancer growth without treatment;
(2) TCR T cell treatment; and (3) a combination of TCR
T cell and IL-2 treatments. These experiments allow us to
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parameter biological meaning
푎 tumor proliferation rate
푏 inverse of tumor carrying capacity
푛 tumor death rate induced by T cells
푑 death rate of T cells
푝 rate of T cell proliferation induced by tumor
푔 steepness coefficient of T cell recruitment
푚 T cell inactivation rate induced by tumor
푝1 rate of T cell proliferation stimulated by IL-2
푔1 steepness of T cell proliferation curve by IL-2
푝2 rate of IL-2 production by T cell and tumor
interaction
푔2 steepness of IL-2 production curve
푘 natural decay rate of IL-2
Table 1
Model parameters and their biological interpretation
parameter units range
푎 푑푎푦−1 [0.01, 0.52]
푏 푐푒푙푙−1 [10−14, 10−4]
푛 푑푎푦−1푐푒푙푙−1 [3.4 ⋅ 10−10, 3 ⋅ 10−7]
푑 푑푎푦−1 [0.01, 0.08]
푝 푑푎푦−1 [0.1, 0.4]
푔 푐푒푙푙 2.019 ⋅ 107
푚 푑푎푦−1푐푒푙푙−1 [10−12, 5 ⋅ 10−7]
푝1 푑푎푦−1 [0.124, 2.971]
푔1 푐푒푙푙푠2 [2 ⋅ 10−6, 2.5063 ⋅ 103]
푝2 퐼푈∕푐푒푙푙푠−1푑푎푦−1 [1, 5]
푔2 푐푒푙푙푠 103
푘 푑푎푦−1 [5, 20]
Table 2
Model parameters and their ranges taken from [42, 31, 30, 34,
32, 29, 35].
Figure 1: A calibration of the tumor growth model Eq. (1) to
the cancer growth data (∙) for the 4050 cell line (left) and the
CaSki cell line (right) without treatment [14].
sequentially estimate the model parameters, and ensure their
robust identification. The ranges of parameters found in the
literature are presented in Table 2 with references. We em-
ploy aMarkov chainMonte Carlo (MCMC) algorithm, namely,
delayed rejection adaptivemetropolis (DRAM) [10]. The fit-
ted parameter values are shown in Table 3.
Fig. 1 shows the experimentla data of tumor growthwith-
out treatment and the fitted logistic growth model (1) for the
two cancer cell lines, 4050 and CaSki. The 4050 cell line
reaches its full capacity around 30 days. This is faster com-
parameters Cancer 4050 Cancer CaSki
푎 0.1828 0.1212
푏 2.6269e-7 1.5201e-7
푝 0.1749 0.2144
푚 7.2590e-8 3.3315e-8
푛 1.2883e-7 7.0924e-9
푑 0.0212 0.0330
푔 1.7479e5 5.0880e5
푝1 0.21441 0.2040
푔1 1.6488 3718
푝2 0 0
푔2 1000 1000
푘 5 10
Table 3
Parameter values obtained with the MCMC algorithm using
the [14] data for the 4050 cell line and the CaSki cell line.
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Figure 2: A calibration of the tumor–immune interaction
model Eqs. (1)–(2) to the cancer growth data with TCR treat-
ment [14]. Two cancer cell lines, 4050 (top) and CaSki (bot-
tom), are treated with TCR T cell with dose 푇 (0) = 105, 106,
and 107.
pared to CaSki. The data with TCR engineered T cell treat-
ment is shown in Fig. 2, where the dosage is given with three
levels, 푇 (0) = 105, 106, and 107. In both 4050 and CaSki
cell lines, the low dose of 푇 (0) = 105 does not prevent tu-
mor progression. However, the higher dose of 푇 (0) = 107
results in tumor regression. The medium dose of 푇 (0) = 106
results with a tumor decay in the 4050 cell line despite its
higher growth rate, but the tumor still grows in the CaSki
cell line. This illustrates different susceptibilities depending
on the type of cancer. The IL-2 treatment is shown to be
effective in both cell lines, where the results are shown in
section 3.3.
3. Results
3.1. Stability analysis reveals critical parameters
for therapy success
The experimental data reveals both scenarios of tumor
progression and regression depending on the initial T cell
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dose. In this section, we study the steady states and their
stability to gain a better understanding of the interaction be-
tween cancer and T cells in the model. We first focus on the
steady states without the IL-2 treatment, that is, (퐶, 푇 , 퐼) =
(퐶, 푇 , 0). We assume that all the parameters are non-negative.
We also assume that 푠푇 (푡) = 0 with a nonzero initial condi-tion for the T cells, since the T cell treatment is given as an
instant treatment at the initial time. The equilibrium states
of the system satisfy
0 = 푎퐶(1 − 푏퐶) − 푛푇퐶 = 퐶[푎(1 − 푏퐶) − 푛푇 ],
0 = −푑푇 + 푝푇 퐶
푔 + 퐶
− 푚퐶푇
= 푇
[
−푑 + 푝 퐶
푔 + 퐶
− 푚퐶
]
,
where the linearized Jacobian is
퐿 =
⎛⎜⎜⎝
푎 − 2푎푏퐶 − 푛푇 −푛퐶
푇
[
푝푔
(푔 + 퐶)2
− 푚
]
−푑 + 푝 퐶
푔 + 퐶
− 푚퐶
⎞⎟⎟⎠ .
There exist four possible steady states (푇 , 퐶). However, the
steady states of interest are those with non-negative values.
In particular, the equilibrium point (푇 , 퐶) = (0, 푏−1) is the
case of tumor cells reaching their maximum capacity, while
the T cells go extinct. This equilibrium state becomes stable
when −푑 + 푝(푔푏 + 1)−1 − 푚푏−1 < 0, which holds if
푝 <
(푚
푏
+ 푑
)
(푔푏 + 1). (4)
Otherwise it is unstable. This provides us with a necessary
condition so that the T cell therapy is successful, that is, the
minimum level of the proliferation rate of T cells that needs
to be attained.
Another set of equilibrium points are (퐶푖, 푇푖) for 푖 = 1and 2, where
퐶푖 =
(푝 − 푑 − 푚푔) ±
√
(푝 − 푑 − 푚푔)2 − 4푚푔푑
2푚
,
and
푇푖 =
푎(1 − 푏퐶푖)
푛
.
For these equilibrium points to be real and positive, it is re-
quired that 푝 − 푑 −푚푔 ≥ 0 and (푝 − 푑 −푚푔)2 − 4푚푔푑 ≥ 0,
or equivalently,
(
√
푑 +
√
푚푔)2 ≤ 푝. (5)
By ordering the points as 0 < 퐶1 < 퐶2, we have 푇1 > 푇2 >
0. We denote (퐶1, 푇1) as the T cell therapy success case thathas a relatively smaller cancer size with a large T cell pop-
ulation. The conditions derived above classify the scenario
of T cell therapy success, particularly relating the model pa-
rameters in terms of the cancer-induced proliferation rate 푝.
In particular, T cell therapy always fails if the cancer induced
proliferation rate is less than (√푑+√푚푔)2. This is the min-
imum level of proliferation rate that should be achieved for
Figure 3: The phase plane of the model (1)–(2) for the 4050
cell line (top) and the CaSki cell line (bottom) in linear (left)
and log (right) scale. ’F’ denotes the initial tumor size and T
cell dosage for which therapy fails and the tumor grows to its
carrying capacity. ’S’ denotes the case when T cell therapy is
successful, and the tumor shrinks to 2.67 × 104 (4050 cell line)
and 1.04 × 105 (CaSki cell line).
the engineered T cells to be effective. On the other hand, if
the T cell proliferation rate is larger than (푚푏−1+푑)(푔푏+1),
the tumor cannot achieve its maximum capacity and the ther-
apy will result in a relatively small tumor equilibrium.
Theorem 1 The T cell therapy fails regardless of the dose if
푝 < (
√
푑+
√
푚푔)2. The therapy succeeds if (푚푏 +푑)(푔푏+1) <
푝. If the T cell proliferation is in the range (
√
푑 +
√
푚푔)2 <
푝 < (푚푏 +푑)(푔푏+1), treatment success depends on the initial
cancer size and T cell dosage.
We note that this result can be used to restrict the search in-
terval when estimating the model parameters. For instance,
the experimental data in [14] show both scenarios of T cell
therapy success and failure, which indicates that the model
should be able to capture both cases. Therefore, we should
search for parameters that satisfy the condition
(
√
푑 +
√
푚푔)2 < 푝 <
(푚
푏
+ 푑
)
(푔푏 + 1). (6)
We remark that the trivial equilibrium state, (푇 , 퐶) = (0, 0),
and the relatively large tumor equilibrium, (푇2, 퐶2), are bothsaddle points. The results are summarized in Table 4 and the
stability analysis and the proof of theorem 1 can be found in
Appendix A.
3.2. A study of the TCR T cell dose depending on
the initial tumor size
The stability analysis of Section 3.1 suggests that if the
parameters satisfy the condition in Eq. (6), the system can
either converge to a therapy success or failure outcome. We
ensured that the parameters identified for the data of the 4050
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condition (0, 0) (0, 1∕푏) (푇1, 퐶1) (푇2, 퐶2)
푝 < (
√
푑 +
√
푚푔)2 saddle stable N/A N/A
(
√
푑 +
√
푚푔)2 < 푝 < (푚
푏
+ 푑)(푔푏 + 1) saddle stable stable saddle
(푚
푏
+ 푑)(푔푏 + 1) < 푝 saddle unstable stable saddle
Table 4
Stability of the equilibrium points as a function of the range of the TCR T cell proliferation
rate 푝.
Figure 4: The long-term dynamics of the 4050 cell line and
the CaSki cell line with TCR T cell treatment for different
dosages. The dosages are chosen to be below (top), within
(middle), and above (bottom) the therapeutic window, that
is, (1.3×106, 3.8×106) and (5.2×106, 5.0×107) for the cell lines
4050 and CaSki, respectively. The initial tumor size is taken as
its carrying capacity, and we show that even in its largest size,
cancer can still be controlled by effective immune intervention
and an appropriate dosage. However, the T cells fail at low
dosages, but also at very high dosage level, due to presumed
premature T cell exhaustion and loss of anti-tumor activity.
Figure 5: The effect of TCR T cell therapy for different levels
of initial cancer size. Treatment with 5 × 105 T cells for the
4050 cell line (left) with size 1 × 106 (top) is successful, but
3×106 (bottom) is not. For the CaSki cell line (right) and the
same T cell dose, cancer of size 5×105 (top) can be successfully
treated, but not a tumor of size 1 × 106 (bottom).
cell line and the CaSki cell line in Fig. 2 fall into this cate-
gory, since the data shows both trajectories depending on the
initial T cell dosage.
With the identified parameters, the phase plane of the
system can provide the effective dose of T cell therapy with
respect to the initial cancer size. Fig. 3 presents the phase
plane of the 4050 and the CaSki cell lines in linear (left) and
log-scale (right). This result provides a suggested minimum
dose of T cell therapy that yields tumor reduction depending
on the initial cancer size, and in fact, a therapeutic window
of T cell dosages. In both cell lines, the smallest experimen-
tal dosage of 105 falls within the range of insufficient dosage,
and cancer eventually grows to its maximum capacity. How-
ever, the medium experimental dosage of 106 is within the
therapeutic window, and despite the initial increase in tumor
burden in the CaSki cell line, the T cells expand and the tu-
mor shrinks.
To study the long-term behavior of the system, the dy-
namics of cancer and T cells up to 1000 days are shown in
Fig. 4. The initial tumor size is taken at the carrying ca-
pacity, that is 푇 (0) = 3.81 × 106 for the 4050 cell line and
6.58 × 106 for the CaSki cell line. The therapeutic win-
dow for this initial cancer size is (1.3 × 106, 3.8 × 106) and
(5.2 × 106, 5.0 × 107), for the 4050 and the CaSki cell lines,
respectively. The results shown in Fig. 4 show the simula-
tion of a TCR T cell dosage that is below, within, and above
the therapeutic window. For the 4050 cell line, we test TCR
T cells dosages of 1.2 × 106, 3.0 × 106, and 5 × 106. The
dosage below the window drives the tumor growth to its ca-
pacity despite its initial decline. On the other hand, the T
cell dose within in the window effectively reduces the can-
cer size from 3.81 × 106 to 2.67 × 104, approximately, 100
times smaller in size.
An interesting observation is the case of a dosage that is
above the therapeutic window. In this case we observe tu-
mor regrowth. The initial reduction of cancer is overturned
and the cancer escapes the TCR T cell therapy after approx-
imately 200 days. The tumor immune escape has been re-
ported not only in an innate immune system [43], but also in
an adoptive immune system [3]. It is presumed that an ex-
treme does with high levels of T cells may cause premature
T cell exhaustion and loss of anti-tumor activity.
For the CaSki cell line, similar results are shown in the
right column of Fig. 4. A TCR T cell dosage within the
range of (5.2×106, 5.0×107) results with a tumor reduction
of approximately 65 times from 6.58 × 106 to 1.04 × 105.
However, for other dosages, therapy fails. Once again we
verify the effective dosage characterized in Fig. 3 by con-
sidering different initial cancer sizes. The results shown in
Fig. 5 are obtained using the T cell dosage of 5×105 for both
cell lines, where the initial cancer size is taken as 1×106 and
3×106 for 4050, and 5×105 and 1×106 for CaSki. While the
dosage of 5 × 105 was sufficient to reduce smaller cancers,
the larger cancers cannot be reduced by this dosage.
The results of this section stress the significance of the
dosage of T cells in driving treatment success, especially
given the toxicity of high-dosages. Moreover, our model
can be used to identify the effective therapeutic window of
T cell dosages in different cancer cell lines as a function of
the initial tumor size. This result can potentially guide future
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therapy design.
3.3. Studying the combination of T cell and IL-2
treatments, and the effect of IL-2 scheduling
In addition to TCR T cell therapy, IL-2 treatment can
stimulate the anti-tumor effect of TCR T cells. The experi-
mental data from [14] provides the IL-2 treatment for three
consecutive days with dosage 198,000 IU. Jin et al. demon-
strate that the combination of TCR T cell and IL-2 treat-
ment is especially valuable when the T cells are given at
low dosages. For instance, the IL-2 treatment did not show
any apparent effect when the T cell therapy is given in high
dosages of 107 cells. However, it improved the T cell treat-
ment in the 4050 cell line treated with 105 cells and in the
CaSki cell line treated with 106 cells. In this section, we cal-
ibrate the model (1–(3) to the experimental data with IL-2
treatment administered at three consecutive days and study
the effect of altering the treatment schedules, while keep-
ing the total dosage administered throughout the treatment
as 594,000 IU.
Figures 6 and 7 present the results of alternating dosage
for the 4050 andCaSki cell lines, respectively. The treatment
is given for 푑 = 3, 4, 5, and 10 consecutive days with a total
dosage of 594, 000∕푑 IU. In the case of the 4050 cell line,
distributing the IL-2 treatment over multiple days improves
the T cell treatment of dosage 105. Figure 6 shows that the
final tumor size is smallest when IL-2 is given for 10 days
with a total dosage of 594, 000 IU. For the T cell dosage of
106, the cancer shrinks in all treatment schedules. However,
the T cells expand to larger magnitudes when IL-2 given for
longer periods. On the other hand, altering the IL-2 schedule
does not affect the T cell treatment outcome in the CaSki cell
line as shown in Figure 7. The tumor size does not change
despite the different IL-2 treatment schedules. The exper-
iments in [14] show that both CD8 and CD4 TCR T cells
are effective for the 4050 cell line, while only CD8 TCR T
cells are cytotoxic in the CaSki cell line. Although we do not
model CD4 and CD8 T cells separately, our results are con-
sistent with the experiments that show that the 4050 cell line
is more affected by the T cell therapy and by the combination
therapy.
4. Conclusion
In this paper, we study the combination of adoptive im-
mune cell transfer therapy using E7 targeted TCR T cell and
IL-2 treatment. By a sequential calibration of the model us-
ing theMCMC algorithm, we obtain the parameter values of
two cancer cell lines, 4050 and CaSki, that agrees with the
experimental data of [14].
We derive a condition for therapy success and failure,
allowing us to study the impact of the T cell activation rate.
This provides tools for calculating theminimum level of TCR
T cell activation rate that is necessary for the treatment to
be successful. When the T cell activation rate is within the
range of potential therapy success, we obtain a therapeutic
window for the T cell dose as a function of the tumor size.
Figure 6: Combination of TCR T cell and IL-2 treatments on
the 4050 cell line for different IL-2 treatment schedules. The
IL-2 is administered for 푑 = 3, 4, 5, 10 days with a total dosage
of 594, 000∕푑 IU. The 10 days schedule shows the biggest im-
provement on T cell therapy.
Figure 7: Combination of T cell and IL-2 treatment on the
CaSki cell line for different IL-2 treatment schedules. The IL-2
is administered for 푑 = 3, 4, 5, 10 days with a total dosage
of 594, 000∕푑 IU. In contrast to 4050 cell line, the combina-
tion therapy outcome does not depend on the IL-2 treatment
schedule.
The results are verified numerically for both cell lines. This
emphasizes that the tumor size should be taken into account
when deciding the dosage, in addition to the general prac-
tice that is based on the weight of the patient. Moreover,
the model illustrates the scenario of toxicity with a high-
dosage of T cell therapy, and treatment failure after transient
regression that has been observed in the adoptive cell ther-
apy community. Finally, the combination of TCR T cell and
IL-2 treatment is studied, where we demonstrate that modi-
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fying the treatment schedule of IL-2 can potentially improve
treating the 4050 cell line, but not the CaSki cell line.
Our future work includesmodeling distinct types of TCR
T cells and immune cells, such as effector, helper, regulatory,
and memory T cells. In addition, we propose to model the
interaction between the immune cells and different cytokines
including IL-2 that can help us understand the complex dy-
namics of the immune system and make robust predictions
regarding the expected outcomes of immunotherapy [27].
In particular, the cytokine release syndrome and neurologic
toxicities are major side effects of adoptive T cell therapy for
which mathematical models can provide insights given the
lack of informative animal models. To improve T cell ther-
apy, we propose to model receptor density and to understand
T cell exhaustion and its effect on off-target cells [21].
A. Steady states
Theorem 1. T cell therapy fails regardless of the dose if
푝 < (
√
푑+
√
푚푔)2. The therapy succeeds if (푚푏 +푑)(푔푏+1) <
푝. If the T cell proliferation is in the range of (
√
푑+
√
푚푔)2 <
푝 < (푚푏 + 푑)(푔푏 + 1), the treatment success depends on the
initial cancer size and the T cell dosage.
PROOF. 1. 푇 = 0 and 퐶 = 0. (푇 , 퐶) = (0, 0) is a saddle,
since the linearized Jacobian reduces to
(
−푑 0
0 푎
)
.
This is a trivial equilibrium state, and at this state,
there is no tumor and no T cells.
2. 푇 = 0 and 푎(1 − 푏퐶) − 푛푇 = 0. Plugging in we have
퐶 = 푏−1 and 푇 = 0. (푇 , 퐶) = (0, 푏−1) is an equilib-
rium state where tumor cells reach maximum capac-
ity, while T cells are absent. The linearized Jacobian
reduces to (
−푑 + 푝
푔푏 + 1
− 푚∕푏 0
−푛∕푏 −푎
)
This point becomes stable when −푑 + 푝푔푏+1 − 푚∕푏 <
0 which holds if 푝 <
(
푚
푏 + 푑
)
(푔푏 + 1), otherwise
becomes unstable.
3. 푎(1 − 푏퐶) − 푛푇 = 0 and −푑 + 푝 퐶푔+퐶 − 푚퐶 = 0.Rearranging we have two equilibrium points
퐶 =
(푝 − 푑 − 푚푔) ±
√
(푝 − 푑 − 푚푔)2 − 4푚푔푑
2푚
and
푇 = 푎(1 − 푏퐶)
푛
so to have real stationary points, we must have (푝 −
푑 − 푚푔)2 − 4푚푔푑 ≥ 0.
(a) 푝 − 푑 − 푚푔 ≥ 0, then we have 푝 ≥ 푑 + 푚푔 +
2
√
푚푔푑 = (
√
푑 +
√
푚푔)2 and two positive 퐶 ,
denoted 0 < 퐶1 < 퐶2.(b) 푝 − 푑 − 푚푔 < 0, then we have 푝 ≤ 푑 + 푚푔 −
2
√
푚푔푑 = (
√
푑 −
√
푚푔)2 and two negative 퐶 .
Note that if we want 퐶 to be non-negative, then con-
dition (a) must hold, i.e, 푝 ≥ (√푑 +√푚푔)2, which is
also consistent with the biological fact that compared
to the apoptosis and the death rate due to competition,
the proliferation or activation rate of T cells must be
at least in the same level. Otherwise tumor cells will
reach their maximum capacity 푏−1.
To check for stability, let 푔(퐶) = −푑 + 푝 퐶푔+퐶 − 푚퐶and equilibrium state (푇 , 퐶) = (푇푖, 퐶푖) with 푖 = 1, 2.Then we have 푇1 > 푇2 > 0, 푔′(퐶1) > 0, 푔′(퐶2) < 0,and the linearized Jacobian reduces to
퐿 =
(
0 푔′(퐶푖)푇푖
−푛퐶푖 −푎푏퐶푖
)
,
푃퐿(휆) = 휆2 + (푎푏퐶푖)휆 + 푛퐶푖푔′(퐶푖)푇푖
The eigenvalues are
휆1,2 =
−(푎푏퐶푖) ±
√
(푎푏퐶푖)2 − 4푛퐶푖푔′(퐶푖)푇푖
2
.
Since 푔′(퐶1) > 0, (푇1, 퐶1) is a stable nodal sink if
(푎푏퐶푖)2 − 4푛퐶푖푔′(퐶푖)푇푖 > 0, a stable twist sink if
(푎푏퐶푖)2 − 4푛퐶푖푔′(퐶푖)푇푖 = 0, and a stable spiral sinkif (푎푏퐶푖)2 − 4푛퐶푖푔′(퐶푖)푇푖 < 0. Since 푔′(퐶2) < 0,
(푇2, 퐶2) is a saddle.
In short, the range in terms of T cell proliferation can be
ordered as
푑 + 푚푔 ≤ 푑 + 푚푔 + 2√푚푔푑 ≤ (푚
푏
+ 푑
)
(푔푏 + 1),
which classifies the stability of the equilibrium points.
□
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